Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Portland, Oregon 97239


The purpose of the blood spot validation portion of the study is to test if measuring female hormone levels in the blood is as accurate through a finger stick, as it is by a blood draw from a vein. The purpose of the feasibility study is to evaluate ovulation occurrence in two populations of oral contraceptive users: heavier and lighter women.

Study summary:

The blood spot validation portion of the study tests the hypothesis that progesterone assays from self-collected daily blood spots are equivalent to serum samples, and that the values obtained can identify women that ovulate. After validating collection methods, enrollment will begin for the feasibility portion of the study looking at thin and heavy women on birth control pills. All women in this portion of the study will take a very-low dose birth control pill that is normally available through a doctor's office. During each month of the study, women will have their blood pressure and weight recorded, and have their blood drawn twice per week or use a finger stick kit daily at home to check for the natural hormones and brain chemicals that tells if an egg develops. During the last week of each menstrual cycle (period week), women will also have their blood drawn to measure the levels of hormone found in the birth control pill. Women will also need to report in a written diary that they have taken their birth control pill for the day.


Inclusion Criteria: - age 18 to 35 - single baseline hematocrit ≥ 36% - single progesterone level of 3 ng/mL or greater during the luteal phase (days 18 to 25) in the menstrual cycle prior to treatment with OCs. Exclusion Criteria: - any absolute contraindications to ethinyl estradiol and levonorgestrel - smoking - actively seeking or involved in a weight loss program (must be weight stable) - pregnancy, breastfeeding, or seeking pregnancy - diagnosis of Polycystic Ovarian Syndrome - recent (8 week) use of OC (patch or ring included), intrauterine, or implantable hormonal contraception - DepoProvera use within six months - current use of drugs that interfere with metabolism of sex steroids.



Primary Contact:

Principal Investigator
Alison Edelman, MD, MPH
Oregon Health and Science University

Backup Contact:


Location Contact:

Portland, Oregon 97239
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.